The effect of statin on the aortic gene expression profiling

International Journal of Cardiology

Volumn 114, Issue 1, 2007, Pages 71-77

  Liu, Shu Lin ^a   Li, Yi Heng ^a   Shi, Guey Yueh ^a   Jiang, Meei Jyh ^a   Chang, Jing Hong ^a   Wu, Hua Lin ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

ApoE deficient mice; Atherosclerosis; Gene expression; Statin

Indexed keywords

ADENOSINE DEAMINASE; APOLIPOPROTEIN; ATRIAL NATRIURETIC FACTOR; CHOLESTEROL; GLUTATHIONE TRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PROTEIN; PROTEIN RGS5; TROPONIN T; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GENE TECHNOLOGY; HYPERCHOLESTEROLEMIA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; AORTA; GENE EXPRESSION; GENE EXPRESSION PROFILING; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL;

EID: 33751225654     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.01.009     Document Type: Article

References (33)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
4. Downs J.R., Clearfield M., Weis S., et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
6. Sever P.S., Dahlöf B., Poulter N.R., et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
7. Halcox J.P., and Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotrophy. Circulation 109 (2004) II42-II48
8. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
9. Chan K.A., Andrade S.E., Boles M., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355 (2000) 2185-2188
10. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
11. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
12. Morikawa S., Takabe W., Mataki C., et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb 9 (2002) 178-183
13. Morikawa S., Takabe W., Mataki C., et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 11 (2004) 62-72
14. Llaverias G., Noe V., Penuelas S., et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun 318 (2004) 265-274
15. Pruitt K.D., Tatusova T., and Maglott D.R. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 33 Database issue (2005) D501-D504
16. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesion of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14 (1994) 133-140
17. Kirsch C., Eckert G.P., and Mueller W.E. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65 (2003) 843-856
18. Johnson-Anuna L.N., Eckert G.P., Keller J.H., et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312 (2005) 786-793
19. Diaz-Zagoya J.C., Asenjo-Barron J.C., Cardenas-Vazquez R., Martinez F., and Juarez-Oropeza M.A. Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet. Life Sci 65 (1999) 947-956
20. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
21. Diomede L., Albani D., Sottocorno M., et al. In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21 (2001) 1327-1332
22. Reddick R.L., Zhang S.H., and Maeda N. Atherosclerosis in mice lacking ApoE: evaluation of lesional development and progression. Arterioscler Thromb 14 (1994) 141-147
23. Jacobson J.R., Dudek S.M., Birukov K.G., et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 30 (2004) 662-670
24. Meske V., Albert F., Richter D., Schwarze J., and Ohm T.G. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci 17 (2003) 93-102
25. Zhou J., Moroi K., Nishiyama M., et al. Characterization of RGS5 in regulation of G protein-coupled receptor signaling. Life Sci 68 (2001) 1457-1469
26. D'Angelo D.D., Sakata Y., Lorenz J.N., et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94 (1997) 8121-8126
27. Geary R.L., Wong J.M., Rossini A., Schwartz S.M., and Adams L.D. Expression profiling identifies 147 genes contributing to a unique primate neointimal smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 22 (2002) 2010-2016
28. Jackson E.K., Koehler M., Mi Z., et al. Possible role of adenosine deaminase in vaso-occlusive diseases. J Hypertens 14 (1996) 19-29
29. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
30. Casco V.H., Veinot J.P., Kuroski de Bold M.L., Masters R.G., Stevenson M.M., and de Bold A.J. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 50 (2002) 799-809
31. Kumar R., Cartledge W.A., Lincoln T.M., and Pandey K.N. Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor block the activation of protein kinase C in vascular smooth muscle cells: role of cGMP and cGMP-dependent protein kinase. Hypertension 29 (1997) 414-421
32. 't Hoen P.A., Van der Lans C.A., Van Eck M., Bijsterbosch M.K., Van Berkel T.J., and Twisk J. Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res 93 (2003) 262-269
33. Wassmann S., Laufs U., Muller K., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 (2002) 300-305